

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT4791996

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT	
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT	
<b>CONVEYING PARTY DATA</b>		
	<b>Name</b>	<b>Execution Date</b>
	BGI SHENZHEN CO., LIMITED	01/24/2018
<b>RECEIVING PARTY DATA</b>		
<b>Name:</b>	MGI TECH CO., LTD	
<b>Street Address:</b>	MAIN BUILDING, SECOND FLOOR OF NO.11 BUILDING, BEISHAN INDUSTRIAL ZONE, YANTIAN DISTRICT	
<b>City:</b>	SHENZHEN, GUANGDONG	
<b>State/Country:</b>	CHINA	
<b>Postal Code:</b>	518083	
<b>PROPERTY NUMBERS Total: 4</b>		
<b>Property Type</b>	<b>Number</b>	
<b>Application Number:</b>	15518760	
<b>Application Number:</b>	15519133	
<b>Application Number:</b>	15519147	
<b>Application Number:</b>	15519149	
<b>CORRESPONDENCE DATA</b>		
<b>Fax Number:</b>	(323)934-0202	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
<b>Phone:</b>	(323) 934-2300	
<b>Email:</b>	LA_Mail@LA.Ladas.com	
<b>Correspondent Name:</b>	LADAS & PARRY LLP	
<b>Address Line 1:</b>	5670 WILSHIRE BOULEVARD, SUITE 2100	
<b>Address Line 4:</b>	LOS ANGELES, CALIFORNIA 90036-5679	
<b>ATTORNEY DOCKET NUMBER:</b>	ASGN18/0014 - DF	
<b>NAME OF SUBMITTER:</b>	MAVIS S. GALLENSON	
<b>SIGNATURE:</b>	/Mavis S. Gallenson/	
<b>DATE SIGNED:</b>	01/24/2018	
<b>Total Attachments: 2</b>		
source=15518760etal_MGI_Tech_US.Assignment#page1.tif		
source=15518760etal_MGI_Tech_US.Assignment#page2.tif		

## ASSIGNMENT

WHEREAS, I/We BGI SHENZHEN CO., LIMITED located at Main Building 11F-3, Beishan Industrial Zone, Beishan Road 146, Yantian District, Shenzhen, China (PRC) 518033 ("Assignor(s)"), is/are the proprietor(s) of invention(s) in the following United States Patent Application(s): (check all that apply):

- ☒ U.S. Patent Application No. 15/518,760 filed on April 12, 2017, entitled "NUCLEIC ACID FRAGMENTATION METHOD AND SEQUENCE COMBINATION".
- ☒ U.S. Patent Application No. 15/519,133 filed on April 13, 2017, entitled "ONE-STOP TREATMENT METHOD FOR BREAKING NUCLEIC ACID BY MEANS OF TRANSPOSASE, AND REAGENT".
- ☒ U.S. Patent Application No. 15/519,147 filed on April 13, 2017, entitled "METHOD FOR BREAKING NUCLEIC ACID AND ADDING ADAPTOR BY MEANS OF TRANSPOSASE, AND REAGENT".
- ☒ U.S. Patent Application No. 15/519,149 filed on April 13, 2017, entitled "MATE PAIR LIBRARY CONSTRUCTION".

WHEREAS, MGI TECH CO., LTD., a company organized and existing under the laws of China (PRC) ("Assignee"), and located at Main Building, Second Floor of No.11 Building, Beishan Industrial Zone, Yantian District, Shenzhen, Guangdong, China (PRC) 518083, is desirous of acquiring the entire right, title and interest in and to the invention(s), the application(s), and any and all Letters Patent or similar foreign or domestic legal protection

- ☒ in the United States
- ☐ in all other countries or jurisdictions;

NOW THEREFORE, for good and valuable consideration, the receipt and adequacy of which is hereby acknowledged,

- a) I/we agree to transfer, and
- b) I/we do hereby transfer,

to Assignee, its successors and assigns, my/our entire right, title and interest in the above named countries and jurisdictions in and to the following including the right to sue for past infringement: the invention(s), the above-identified application(s), all applications from which any of the above-identified application(s) claim priority, corresponding U.S. and non-U.S. applications, any continuation, continuation-in-part, division, renewal, or substitute for the applications, all Letters Patent, any reissue, re-examination, or similar legal protection issuing related to the Letters Patent, and all rights and benefits under any applicable treaty or convention, and I/we authorize the Director of the United States Patent and Trademark Office or foreign equivalent to issue the Letters Patent or similar legal protection to the Assignee.

I/We authorize the Assignee, its successors and assigns, or anyone it may properly designate, to apply for Letters Patent or similar legal protection, in its own name if desired, in the above named countries and jurisdictions and appoint Assignee the common representative in the above identified international application and any international application for the invention.

I/We represent to the Assignee, its successors and assigns, that I/we shall not execute any writing or do any act whatsoever conflicting with this Assignment. I/We, my/our executors or administrators, will at any time upon request, without additional consideration, but at the expense of the Assignee, its successors and assigns, execute and deliver to Assignee or its legal representatives such additional writings and do such additional acts as the Assignee, its successors and assigns, may deem desirable to perfect its enjoyment of this grant, and render all assistance in making application for and obtaining, maintaining, and enforcing the Letters Patent or similar legal protection on the invention in any and

all countries and jurisdictions, including without limitation providing testimony in any related interference, litigation or proceeding. To the extent that I/we, my/our executors or administrators are unable or unavailable to execute and deliver to Assignee or its legal representatives such additional writings and do such additional acts as Assignee, its successors and assigns may deem desirable to perfect its enjoyment of this grant, and render all assistance in making application for and obtaining, maintaining, and enforcing the Letters Patent or similar legal protection on the invention in any and all countries and jurisdictions, I/we, my/our executors or administrators hereby authorize Assignee, its successors and assigns to act on my/our behalf/belhalves.

If any provision(s) of this Assignment are held unenforceable or in conflict with the law of any jurisdiction, the validity of the remaining provisions will not be affected by such holding and the part held unenforceable in or in conflict with the law of one jurisdiction will remain in effect for other jurisdictions until held unenforceable or in conflict with the law of that jurisdiction.

**BGI SHENZHEN CO., LIMITED**

[X] xing wei

Name/Title: xing wei, ZP Director  
(Assignor)

24 Jan. 2018  
Date

~~~~~  
**MGI TECH CO., LTD**

[X] xing wei

Name/Title: xing wei, ZP Director  
(Assignee)

24 Jan. 2018  
Date